Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologySummaCare Oncology Infusion Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy POS-ONC-001

    Place of Service Policy: Oncology Infusion Site of Care Management

    Customize your policy alerts

    Sign up for summacare Policy POS-ONC-001 alerts

    Get alerted when Policy POS-ONC-001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and site-of-care decisions for oncology infusion drugs on SummaCare's Site of Care Redirect Drug List. Administration is directed to a physician office or home-based setting unless individualized clinical documentation supports hospital outpatient administration.

    Policy Summary
    PayerSummaCare
    PolicyPlace of Service Policy: Oncology Infusion Site of Care Management
    Policy CodePolicy POS-ONC-001
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for oncology infusion drugs on the Site of Care Redirect Drug List, including the drug, place of service, and member information.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    POS 11 or 12Required preferred settings
    POS 19 or 22Non-preferred settings requiring an exception
    7Clinical exception categories
    2Drugs subject to site-of-care redirection
    1 doseMaximum first-dose waiver
    10 yearsMinimum documentation retention

    Site-of-Care Coverage Criteria

    Preferred Setting Authorization

    Preferred-setting authorization is approved when ALL of the following are met.

    Preferred Setting Authorization: The drug is on the Site of Care Redirect Drug List; medical necessity for the drug is established; and the provider confirms the ability to administer the drug in a Preferred Setting or agrees to coordinate care with a Preferred Setting provider.

    No site-of-care exception documentation is required.

    Non-Preferred Setting Authorization

    Non-preferred-setting authorization requires ALL threshold conditions AND at least one documented clinical exception.

    Non-Preferred Setting Threshold Conditions: Medical necessity for the requested drug is established; the facility is a licensed hospital outpatient department under POS 19 or POS 22; the treating physician submits a written attestation specific to the member's current clinical status that the member's condition requires a higher level of care than a Preferred Setting can provide; and the treating physician confirms in writing that the Non-Preferred Setting is required for this drug and this member, not merely that the hospital is the physician's preferred practice location.POS 19 or POS 22

    Templated or pre-populated attestations are not acceptable.

    Clinical Exception

    • Exception A: Severe Adverse Drug Reaction or Anaphylaxis History: For initiation of a new drug or drug class, the member has a documented Grade 3 or higher CTCAE severe adverse drug reaction or anaphylaxis to a prior drug in the same class or with a closely related mechanism of action, requiring emergency medical intervention.Grade 3 or higher CTCAE, or anaphylaxis

      Applies to initiation only and ends after one full tolerated dose of the specific drug.

    • Exception B: Cytokine Release Syndrome Risk: The specific drug has an established CRS risk under FDA labeling or current NCCN Guidelines, and the member has individualized risk factors placing the member at elevated risk beyond the general patient population.Time-limited to the heightened-risk period

      Fresh documentation is required at each renewal.

    • Exception C: Significant Cardiac or Pulmonary Comorbidity: A documented cardiac or pulmonary condition materially increases adverse-reaction risk during infusion and requires monitoring available only in a hospital outpatient department.

    Exception F — Cognitive Conditions or Mental Status Changes

    Covered as a clinical exception when all of the following are met.

    Cognitive condition or acute mental-status exception: The member has a documented cognitive condition or acute mental-status change that materially impacts infusion safety in a non-hospital setting and requires the continuous monitoring capability of a hospital outpatient department.

    Stable cognitive conditions routinely managed in outpatient settings do not qualify; the condition must be acute, unstable, or of a severity requiring continuous observation during infusion.

    Exception G — Documented Clinical Contraindication to Preferred Setting

    Covered as a narrow clinical exception when all of the following are met.

    Documented clinical contraindication: The member's medical condition is formally documented as clinically contraindicated for any Preferred Setting based on individualized clinical factors.

    The request must address a genuinely unusual clinical circumstance. Stable profiles, prior tolerance of the same drug in a Preferred Setting, provider preference, logistical convenience, and lack of a conveniently located in-network Preferred Setting provider do not qualify.

    5.3 First-Dose Accommodation

    A single first-dose waiver may be granted when all of the following are met.

    First-dose accommodation: The member is initiating a new drug, and the treating physician documents that the first dose warrants heightened monitoring due to the drug's known side-effect profile, the member's clinical history, or both.One dose or one infusion encounter

    The authorization must be explicitly limited to one dose or one infusion encounter. The treating physician must commit in writing to transition subsequent maintenance doses to a Preferred Setting absent a separately documented exception. The waiver does not renew automatically, and a member who received a waiver for the same drug within the preceding 12 months is not eligible for another.

    Non-Preferred Reauthorization and Transition

    Continued Non-Preferred authorization requires all of the following.

    Ongoing exception eligibility: The applicable clinical exception continues to meet policy criteria, fresh documentation confirming continued applicability of the exception is submitted for each renewal, and any required transition to a Preferred Setting is documented or initiated.Each renewal

    Non-Preferred authorizations do not carry forward automatically. Supporting documentation must be present in the medical record at the time of the request; post-hoc documentation will not be credited.

    This policy does not apply to emergency department encounters (POS 23), inpatient hospital admissions (POS 21), or drugs administered exclusively in an inpatient setting for reasons unrelated to site-of-care optimization.

    Provider preference, logistical convenience, and the lack of a conveniently located in-network Preferred Setting provider are not qualifying clinical exceptions for Non-Preferred Setting authorization.

    A stable clinical profile or prior tolerance of the same drug in a Preferred Setting does not establish a clinical contraindication to a Preferred Setting. Hospital outpatient administration must be supported by an individualized safety concern meeting the applicable exception criteria, not by routine use or convenience.

    A provider's primary practice location being a hospital outpatient department does not, by itself, constitute a clinical basis for Non-Preferred Setting authorization. The request must be supported by member-specific clinical documentation.

    Hospital outpatient administration is not supported solely by broad clinical language, templated or pre-populated attestations, provider preference, administrative convenience, stable clinical profiles, or prior tolerance of the same drug in a Preferred Setting. Non-Preferred authorization requires affirmative, individualized documentation addressing the specific clinical exception.

    Coding and Routing Reference

    Preferred SettingsRevenueCovered
    POS 11Physician office; includes a stand-alone infusion center affiliated with a physician practice
    POS 12Member's home
    Non-Preferred Settings Requiring Clinical ExceptionRevenue
    POS 19Off-campus hospital outpatient department
    POS 22On-campus hospital outpatient department
    Excluded EncountersRevenueNot Covered
    POS 21Inpatient hospital admission
    POS 23Emergency department encounter
    Xgeva and Associated BiosimilarsHCPCSCovered
    J0897XGEVA; Denosumab; Subcutaneous
    Q5136Denosumab-bbdz; Wyost
    Q5157Denosumab-bmwo; Osenvelt
    Q5158Denosumab-bnht; Bomyntra
    C9399Denosumab-desu; Jubereq
    J3590Denosumab-desu; Jubereq
    Q5159Denosumab-dssb; Xbryk
    Q5161Denosumab-kyqq; Aukelso
    Q5162Denosumab-nxxp; Bilprevda
    C9399Denosumab-mobz; Oziltus
    1–10 of 13
    1/2
    Prolia and Associated BiosimilarsHCPCSCovered
    J0897PROLIA; Denosumab; Subcutaneous
    C9399Denosumab-adet; Ponlimsi
    J3490Denosumab-adet; Ponlimsi
    J3590Denosumab-adet; Ponlimsi
    J9999Denosumab-adet; Ponlimsi
    Q5136Denosumab-bbdz; Jubbonti
    Q5157Denosumab-bmwo; Stoboclo
    Q5158Denosumab-bnht; Conexxence
    C9399Denosumab-desu; Osvyrti
    J3590Denosumab-desu; Osvyrti
    1–10 of 17
    1/2
    Place of Service Routing Codesmixed
    11Place of service used in the Preferred Setting routing rule
    12Place of service used in the Preferred Setting routing rule
    19Place of service used in the Non-Preferred Setting review rule
    22Place of service used in the Non-Preferred Setting review rule
    Severe Prior Adverse Drug Reaction
    Severity thresholdGrade 3 or higher per CTCAE, or anaphylaxis requiring emergency medical intervention
    When it appliesInitiation of a new drug or drug class only
    Required supportClinical notes must document the prior reaction, severity grade, and rationale for hospital-level monitoring at initiation
    Renal Laboratory Recency
    Laboratory timeframeCurrent laboratory values must be from within the prior 30 days

    Authorization, Documentation, and Review Actions

    Prior Authorization

    Submit Site-of-Care Authorization

    Submit an oncology infusion site-of-care prior authorization to EviCore for drugs on the SummaCare Site of Care Redirect Drug List. EviCore reviews and redirects requests under this policy, and Non-Preferred Site authorization requires individualized clinical documentation.

    • Applies to participating and non-participating providers across SummaCare commercial lines.
    • Emergency department encounters, inpatient admissions, and drugs administered exclusively inpatient for unrelated reasons are outside this policy.
    Prior Authorization

    Preferred Setting Approval Requirements

    Preferred Setting authorization at POS 11 or POS 12 is approved when the drug is on the Redirect Drug List, medical necessity is established, and the provider can administer the drug in a Preferred Setting or coordinate care to a Preferred Setting provider.

    • No site-of-care exception documentation is required for Preferred Setting authorization.

    Policy Background

    This policy is a site-of-care management policy, not a drug-specific oncology treatment guideline. It governs prior authorization and directs oncology infusion drugs on the Site of Care Redirect Drug List to a Preferred Setting—a physician office or home-based setting—when clinically appropriate. Hospital outpatient administration is considered only when individualized documentation demonstrates a qualifying clinical safety exception, such as severe prior reactions, elevated cytokine release syndrome risk, unstable organ function, difficult vascular access, cognitive instability, or another documented contraindication.

    Key Definitions

    Preferred Setting
    LocationsA physician office, a stand-alone infusion center affiliated with a physician practice, or the member's home
    Place of servicePOS 11 for a physician office or affiliated stand-alone infusion center; POS 12 for the member's home
    Policy roleRequired default for all drugs subject to this policy
    Non-Preferred Setting
    LocationsAn on-campus hospital outpatient department or an off-campus hospital outpatient department
    Place of servicePOS 22 is on-campus; POS 19 is off-campus
    Authorization requirement

    Covered Denosumab Regimens

    Generic nameBrand nameHCPCS code(s)RouteCoverage
    DenosumabXgevaJ0897SubcutaneousCovered
    Denosumab-bbdzWyostQ5136Covered
    Denosumab-bmwoOsenveltQ5157Covered
    Denosumab-bnhtBomyntraQ5158Covered
    Denosumab-desuJubereqC9399 / J3590Covered
    Denosumab-dssbXbrykQ5159Covered
    Denosumab-kyqqAukelsoQ5161Covered
    Denosumab-mobzOziltusC9399 / J3590Covered
    Denosumab-nxxpBilprevdaQ5162Covered
    Denosumab-qbdeXtrenboC9399 / J3590Covered
    Generic nameBrand nameHCPCS code(s)RouteCoverage
    DenosumabProliaJ0897SubcutaneousCovered
    Denosumab-adetPonlimsiC9399 / J3490 / J3590 / J9999Covered
    Denosumab-bbdzJubbontiQ5136Covered
    Denosumab-bmwoStobocloQ5157Covered
    Denosumab-bnhtConexxenceQ5158Covered
    Denosumab-desuOsvyrtiC9399 / J3590Covered
    Denosumab-dssbOspomyvQ5159Covered
    Denosumab-kyqqBosayaQ5161Covered
    Denosumab-mobzBoncresaC9399 / J3590Covered
    Denosumab-nxxpBildyosQ5162Covered
    Denosumab-qbdeEnobyC9399 / J3590Covered
    Policy Summary
    PayerSummaCare
    PolicyPlace of Service Policy: Oncology Infusion Site of Care Management
    Policy CodePolicy POS-ONC-001
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for oncology infusion drugs on the Site of Care Redirect Drug List, including the drug, place of service, and member information.
    SourceLink
    On This Page
    Site-of-Care Coverage CriteriaCoding and Routing ReferenceAuthorization, Documentation, and Review ActionsPolicy BackgroundKey DefinitionsCovered Denosumab Regimens
    Condition must be unstable, poorly controlled, or documented as creating elevated infusion risk

    Stable, well-controlled conditions do not qualify.

  1. Exception D: Unstable Renal Function: Documented unstable renal function impairs safe fluid-balance management outside a hospital outpatient setting.Current laboratory values within 30 days

    Stable chronic kidney disease alone does not qualify; updated laboratory values are required at each renewal.

  2. Exception E: Difficult or Unstable Vascular Access: Documented difficult or unstable vascular access cannot be safely managed in a Preferred Setting and requires hospital-level nursing or procedural resources.Objective access difficulty, failed attempts, or device complication

    A functioning uncomplicated central venous access device does not qualify absent dysfunction or complication.

  3. Exception F: Cognitive Conditions or Mental Status Changes: A documented cognitive condition or acute mental-status change materially affects infusion safety in a non-hospital setting and requires continuous hospital outpatient monitoring.Acute, unstable, or severe condition requiring continuous observation

    Stable cognitive conditions routinely managed in outpatient settings do not qualify.

  4. Exception G: Clinical Contraindication to Preferred Setting: The member's condition is formally documented as clinically contraindicated for any Preferred Setting based on individualized clinical factors.Specific individualized contraindication

    Provider preference, logistical convenience, and lack of a conveniently located in-network Preferred Setting provider do not qualify.

  5. Required findings
    Values must demonstrate unstable or significantly impaired renal function, such as acute kidney injury, rapidly declining GFR, or dialysis dependence
    Renewal requirementUpdated laboratory values are required at each renewal
    Prior-Dose Guardrail
    Termination pointThe exception ends after at least one full dose of the specific drug is received and tolerated in any setting
    ScopeThe guardrail applies to the severe adverse drug reaction or anaphylaxis exception
    After terminationSubsequent authorizations must be at a Preferred Setting unless a separate exception applies
    Prior Authorization

    Hospital Outpatient Exception Authorization

    A request for hospital outpatient administration at POS 19 or POS 22 must satisfy every threshold condition and document at least one qualifying clinical exception. Authorization is not automatic and requires affirmative, individualized support for the member and drug.

    • Establish medical necessity for the requested drug.
    • Confirm the facility is a licensed hospital outpatient department under POS 19 or POS 22.
    • Submit a current, member-specific treating physician attestation that the member requires a higher level of care than a Preferred Setting can provide.
    • Confirm in writing that the Non-Preferred Setting is required for this drug and member, not merely preferred by the physician.
    Prior Authorization

    Submit Site-of-Care Prior Authorization

    Submit the prior authorization with the requested drug, place of service, and member information. EviCore verifies whether the drug is on the Redirect Drug List, assesses the requested POS, and applies the Preferred or Non-Preferred review pathway.

    • POS 11 or 12 proceeds to Preferred Setting approval and medical-necessity review.
    • POS 19 or 22 requires exception documentation under the Non-Preferred review process.
    • If the drug is not on the Redirect Drug List, standard workflow applies.
    Documentation Required

    Non-Preferred Exception Review

    For a Non-Preferred request, provide exception documentation under the policy and participate in clinical review. EviCore's clinical reviewer assesses the documentation against the exception criteria, with peer-to-peer review available.

    • Documentation must support both all threshold conditions and at least one clinical exception.
    • Provider contact may be required to obtain missing exception documentation.
    Billing Rule

    Coordinate Third-Party Drug Supply

    When a clinical exception is approved for hospital-based administration, SummaCare may coordinate direct drug supply from a designated specialty pharmacy or third-party supplier. Providers will be notified in advance; the coordination does not change the clinical exception criteria or care.

    • Maintain the approved Non-Preferred authorization and coordinate with the designated supplier as directed.
    Prior Authorization

    Transition After First Dose or Time-Limited Exception

    A first-dose waiver is limited to one dose or infusion encounter and requires a written commitment to transition subsequent maintenance doses to a Preferred Setting. Time-limited exceptions likewise require transition when the documented risk window ends.

    • The same-drug first-dose waiver is unavailable if one was received within the preceding 12 months.
    • Subsequent Non-Preferred authorization requires a separately documented exception.
    Documentation Required

    Provide Contemporaneous Records and Attestation

    Base every Non-Preferred exception request on contemporaneous clinical notes, laboratory results, or medical records from the treating provider, together with a treating physician or qualified advanced practice provider attestation addressing the member's current status. Retrospective records created after an audit inquiry are insufficient.

    • Attestations must be individualized and specific to the member's current clinical status.
    • Templated or pre-populated attestations are not acceptable.
    Documentation Required

    Document Prior Severe Reaction

    For a prior severe reaction exception, document a Grade 3 or higher CTCAE reaction or anaphylaxis to a prior drug in the same class or with a closely related mechanism of action, including emergency intervention and the rationale for hospital-level monitoring.

    • Include clinical notes, reaction severity grade, emergency intervention, and treating physician rationale.
    • The exception applies only when initiating a new drug or drug class.
    Documentation Required

    Document Individualized CRS Risk

    For a CRS-risk exception, document that the specific drug has an established CRS risk under FDA labeling or current NCCN Guidelines and explain why this member's individual profile creates elevated risk beyond the general patient population.

    • Address member-specific factors such as high tumor burden, prior CRS, or advanced disease.
    • Fresh documentation is required at each renewal, and authorization must match the heightened-risk period.
    Documentation Required

    Document Cardiopulmonary Monitoring Need

    For a cardiac or pulmonary exception, submit objective evidence and a physician explanation connecting the condition to a need for hospital-level infusion monitoring for the specific drug.

    • Examples include echocardiogram results, pulmonary function tests, or a specialist consultation note.
    • Stable, well-controlled conditions without incremental infusion risk do not qualify.
    Documentation Required

    Document Current Renal Function

    For an unstable renal function exception, provide current laboratory evidence and a treating physician statement explaining why hospital monitoring is needed for fluid and electrolyte management.

    • Laboratory values must be from within the prior 30 days and demonstrate instability or significant impairment.
    • Examples include acute kidney injury, rapidly declining GFR, or dialysis dependence.
    • Updated laboratory values are required at each renewal.
    Documentation Required

    Document Vascular Access Problem

    For a vascular-access exception, document why access cannot be safely managed in a Preferred Setting and why hospital nursing or procedural resources are required.

    • Include failed access attempts, implanted-device complications, or other objective access challenges.
    • A statement that the member has 'poor veins' without clinical detail is insufficient.
    • A functioning, uncomplicated port or PICC does not qualify without documented dysfunction or complication.
    Documentation Required

    Document Cognitive or Mental-Status Risk

    For a cognitive or mental-status exception, submit clinical notes from the treating physician or specialist describing the specific condition, its current severity, and why continuous hospital outpatient monitoring is required for safe infusion.

    • The condition must be acute, unstable, or severe enough to require continuous observation.
    • Stable cognitive conditions routinely managed in outpatient settings do not qualify.
    Documentation Required

    Document Other Clinical Contraindication

    For an unusual clinical contraindication to a Preferred Setting, obtain a detailed letter from the treating oncologist addressing the member's current status, requested drug, specific contraindication, and clinical rationale precluding Preferred Setting administration.

    • The exception is limited to circumstances not captured by Exceptions A-F.
    • Administrative representatives may not substitute for the treating oncologist.
    • Provider preference, convenience, or lack of a nearby in-network Preferred Setting does not qualify.
    Documentation Required

    Support Cognitive or Mental-Status Exception

    Cognitive or acute mental-status exceptions require clinical notes that support the member's current condition, severity, impact on infusion safety, and need for continuous hospital-level observation.

    • Generic cognitive diagnoses or stable outpatient-managed conditions are insufficient.
    • Documentation must explain why a Preferred Setting cannot safely provide the required oversight.
    Documentation Required

    Submit Clinical Contraindication Letter

    A Preferred-Setting contraindication must be addressed in an individualized treating oncologist letter that identifies the specific clinical factor preventing administration at POS 11 or POS 12.

    • Address the member's current clinical status and the requested drug.
    • Explain the clinical rationale linking the contraindication to hospital outpatient administration.
    Documentation Required

    Document First-Dose Waiver

    A first-dose waiver requires documentation that heightened monitoring is warranted because of the drug's known side-effect profile, the member's clinical history, or both. The request must be limited to one dose and include a written transition commitment.

    • Do not treat a first-dose waiver as continuing authorization.
    • Plan and document transition to a Preferred Setting for subsequent maintenance doses.
    Documentation Required

    Provide Concurrent and Renewal Documentation

    Each renewal or concurrent Non-Preferred authorization request must include fresh, contemporaneous documentation confirming that the exception still applies. Prior approval does not carry forward automatically.

    • Renewals must reflect current clinical status and any exception-specific update requirements.
    • CRS-risk renewals require fresh member-specific risk documentation.
    • Renal-function renewals require current laboratory values within the prior 30 days.

    Unsupported block type: denial_risk

    Denial Risk

    No Qualifying Clinical Exception

    A Non-Preferred request may be denied when no qualifying clinical exception is documented or when the submission is generic, unsupported, or unrelated to the member's individualized clinical need.

    • At least one exception under Section 5.2.2 must be supported in addition to all threshold conditions.
    • General drug-class risk, stable conditions, convenience, and generic attestations are insufficient.
    Denial Risk

    Prior Reaction Exception No Longer Available

    The prior-reaction exception ends once the member has received and tolerated at least one full dose of the specific drug in any setting. Subsequent requests must use a Preferred Setting unless a separate exception is documented.

    • Do not rely on the prior-reaction exception for later doses of a tolerated drug.
    Denial Risk

    Renewal or Current-Status Requirements Not Met

    A renewal or current-status exception request may be denied when required fresh documentation is missing, including current CRS-risk assessment, renal laboratory evidence, or other updated clinical support.

    • Time-limited exceptions must be supported for the current risk window.
    • Renal exception renewals require laboratory values from within the prior 30 days.
    Denial Risk

    Insufficient Clinical Severity or Rationale

    An exception is not supported by a condition that is stable, controlled, uncomplicated, or insufficiently severe to require hospital-level monitoring. The clinical record must show meaningful incremental infusion risk and a specific rationale for the Non-Preferred Setting.

    • Stable cardiac, pulmonary, cognitive, or renal conditions generally do not qualify without documented instability or elevated risk.
    • A functioning, uncomplicated vascular-access device does not establish an exception.
    Denial Risk

    Unsupported Preferred-Setting Contraindication

    A Preferred-Setting contraindication may be denied when the treating oncologist has not provided individualized documentation and a specific clinical rationale linking the member's condition and requested drug to the contraindication.

    • Routine use, stable profiles, prior tolerance in a Preferred Setting, provider preference, and logistical convenience do not qualify.
    Denial Risk

    First-Dose Waiver Requirements Not Met

    A first-dose waiver may be denied when the record does not explain the drug-specific or member-specific need for heightened monitoring, does not limit approval to one dose, or lacks a written transition commitment.

    • The waiver does not renew automatically.
    • A separate documented exception is required for subsequent Non-Preferred doses.
    Denial Risk

    Repeat First-Dose Waiver Prohibited

    A first-dose waiver for the same drug is prohibited when the member received a first-dose waiver for that drug within the preceding 12 months.

    • Verify the member's waiver history before submitting or renewing a request.
    Denial Risk

    Audit, Recoupment, and Transition Exposure

    Providers must maintain contemporaneous records supporting the authorization and comply with transition obligations. SummaCare may audit Non-Preferred authorizations, recoup the cost differential when criteria were not met, and deny subsequent requests when required transition is not documented or initiated.

    • Post-hoc documentation created after an audit inquiry will not be credited.
    • Time-limited exceptions require transition to a Preferred Setting.
    • Patterned or identical attestations across members may trigger heightened scrutiny.
    Denial Risk

    No Automatic Reauthorization

    Non-Preferred authorizations do not automatically reauthorize. Every renewal requires fresh documentation confirming that the exception remains clinically applicable.

    • A prior approval alone is not sufficient for the next authorization period.
    • Failure to document continuing applicability may result in denial.
    Denial Risk

    Appeal Requires Specific Clinical Basis

    An appeal based only on provider preference, practice location, logistical convenience, or general disagreement with the policy will not support approval. Submit additional clinical documentation addressing the specific exception criteria.

    • A treating physician may request peer-to-peer review with an EviCore medical director within two business days of determination.
    • A formal written appeal with additional supporting documentation may be submitted within 30 calendar days.
    Requires a documented clinical exception
    Drug List
    SourceAttachment A
    PurposeLists the drugs managed by eviCore's Point of Service program
    Policy useDrugs on this list are subject to the site's authorization and setting requirements
    Documentation of Record
    Acceptable recordsContemporaneous clinical notes, laboratory results, or medical records from the treating provider
    PurposeForms the basis for a Non-Preferred Site exception
    Timing restrictionRetrospective documentation added after an audit inquiry is insufficient
    Treating Physician
    Who qualifiesThe licensed physician or advanced practice provider responsible for the member's oncology care
    Authorization roleSubmits or supervises the prior authorization request
    Clinical responsibilityIs responsible for the member's oncology care
    Cognitive Condition or Acute Mental-Status Exception
    Qualifying conditionA documented cognitive condition or acute mental-status change
    Safety impactThe condition materially impacts infusion safety in a non-hospital setting
    Monitoring requirementContinuous monitoring capability of a hospital outpatient department is required; stable outpatient-managed conditions do not qualify
    Clinical Contraindication to Preferred Setting
    DefinitionAn individualized medical circumstance formally documented as clinically contraindicating administration in any Preferred Setting
    DocumentationA detailed letter from the treating oncologist must address the specific contraindication, current clinical status, requested drug, and clinical rationale
    Non-qualifying reasonsProvider preference, logistical convenience, and lack of a conveniently located in-network Preferred Setting provider do not qualify
    First-Dose Accommodation
    Authorization scopeA single authorization for one dose or one infusion encounter at a Non-Preferred Setting
    EligibilityAvailable for a member initiating a new drug when the first dose warrants heightened monitoring
    Transition requirementThe treating physician must commit in writing to transition subsequent maintenance doses to a Preferred Setting unless a separately documented exception applies